Research brief

Tesamorelin Blood Work Labs: What to Check Before & After

Q: What labs are required before starting tesamorelin?

Baseline labs before starting tesamorelin must include IGF-1, fasting glucose, HbA1c, a complete lipid panel (total cholesterol, LDL, HDL, triglycerides), and liver enzymes (ALT, AST). IGF-1 establishes your pre-treatment growth hormone activity level, glucose and HbA1c screen for insulin resistance risk, lipids provide a baseline for tracking tesamorelin’s primary metabolic benefit, and liver enzymes rule out hepatic contraindications. Skipping any of these markers leaves blind spots in safety and efficacy monitoring.

Q: How often should IGF-1 be checked during tesamorelin therapy?

IGF-1 should be checked at baseline before starting tesamorelin, rechecked at 8 weeks to confirm growth hormone stimulation occurred, and then monitored every 12–16 weeks during long-term therapy if dose adjustments are being considered. The 8-week recheck is the most critical — it’s the earliest reliable point to confirm whether tesamorelin is delivering the intended pituitary response. IGF-1 levels should rise 30–80% above baseline in responders; flat or minimal increases indicate non-response and require protocol revision.

Q: Can tesamorelin cause diabetes or high blood sugar?

Tesamorelin does not directly cause diabetes, but it can worsen insulin resistance in patients with pre-existing metabolic dysfunction because growth hormone interferes with insulin receptor signalling. Clinical data show that 15–20% of tesamorelin users experience fasting glucose elevations requiring dietary intervention or dose reduction. Patients with baseline fasting glucose above 95 mg/dL or HbA1c above 5.5% have the highest risk and should recheck glucose at 4 weeks instead of 8 weeks to catch early changes.

Q: What happens if my fasting glucose rises on tesamorelin?

If fasting glucose rises more than 10 mg/dL during tesamorelin therapy, immediate carbohydrate restriction (below 100g daily) typically reverses the elevation within 2 weeks. If glucose remains elevated despite dietary changes, reducing tesamorelin dose from 2mg to 1mg daily often restores glucose control while preserving partial metabolic benefit. Discontinuing tesamorelin entirely causes glucose to return to baseline within 4–6 weeks as growth hormone levels normalise and insulin sensitivity recovers.

Q: How long does it take for tesamorelin to improve lipid panels?

Tesamorelin-induced lipid improvements become measurable at 12 weeks in most responders, with triglyceride reductions of 15–25% and LDL reductions of 8–12% documented in clinical trials. Maximal lipid-modulating effects occur at 24–26 weeks of continuous therapy. Patients who don’t show any triglyceride or LDL improvement by 16 weeks are unlikely to achieve lipid benefits even with extended use, and the protocol should be re-evaluated for adherence, dietary confounders, or non-response.

Q: What does it mean if my IGF-1 stays the same after starting tesamorelin?

Flat IGF-1 levels after 8 weeks on tesamorelin indicate non-response — the peptide is not effectively stimulating growth hormone secretion from the pituitary gland. Common causes include inconsistent injection timing, improper peptide storage leading to degradation, or underlying pituitary dysfunction. Before assuming pituitary failure, verify injection technique, confirm daily dosing at the same time, and ensure the peptide was stored at 2–8°C after reconstitution. If IGF-1 remains unchanged after protocol correction, endocrinologist consultation is warranted.

Q: Do I need liver enzyme tests while on tesamorelin?

Baseline liver enzyme testing (ALT, AST) is recommended before starting tesamorelin, especially for patients with known liver disease, alcohol use, or metabolic syndrome. Growth hormone can transiently elevate liver enzymes in 5–10% of users, typically resolving without intervention. Routine monitoring during therapy is not required unless baseline enzymes were borderline high (ALT >35 U/L, AST >30 U/L), in which case rechecking at 8 weeks and quarterly thereafter is prudent.

Real Peptides Research TeamEditorial

Updated May 4, 20267 min read

58 WORDS

Short answer

Most patients starting tesamorelin focus on injection technique. But the labs tell you whether the peptide is working or causing harm. Baseline IGF-1 levels before your first injection determine whether you're a responder or non-responder six weeks later. Skipping the pre-treatment glucose panel means you won't catch insulin resistance developing at week eight when it's easiest to reverse.

Key takeaways

Baseline IGF-1 before starting tesamorelin is non-negotiable. Without it, you cannot measure the peptide's efficacy at week eight when response assessment matters most.
Fasting glucose and HbA1c must be checked at baseline and rechecked at 8 weeks because growth hormone-induced insulin resistance develops early and is reversible if caught before HbA1c crosses 6.5%.
Tesamorelin's lipid-modulating effects. Triglyceride reductions of 15–25% and LDL reductions of 8–12%. Are visible in lab work by 12 weeks in responders and represent the peptide's primary FDA-approved outcome.
IGF-1 increases of 30–80% above baseline within 8 weeks distinguish responders from non-responders; flat or minimal IGF-1 rise indicates pituitary dysfunction or dosing error.
Quarterly HbA1c and lipid monitoring during long-term tesamorelin use catches metabolic drift before it becomes irreversible. Skipping follow-up labs after month three is the most common monitoring failure.

We've worked with hundreds of researchers running tesamorelin protocols. The gap between rigorous monitoring and reactive troubleshooting is almost always visible in the lab work. Specifically in the timing and panel selection most protocols ignore.

What labs should you check before and after starting tesamorelin?

Before starting tesamorelin, baseline labs must include IGF-1 (insulin-like growth factor 1), fasting glucose, HbA1c (glycated haemoglobin), lipid panel (total cholesterol, LDL, HDL, triglycerides), and liver enzymes (ALT, AST). After initiating therapy, IGF-1 and glucose markers should be rechecked at 8 weeks to confirm response and safety, then quarterly during continued use. Tesamorelin stimulates growth hormone release, and IGF-1 serves as the downstream biomarker proving that mechanism is active. Without IGF-1 data, efficacy cannot be assessed.

Yes, tesamorelin blood work labs are protocol-dependent. But the core monitoring framework is standardised across clinical and research settings. What varies is the frequency and depth of follow-up based on individual metabolic risk factors. Here's what baseline testing must capture, what the 8-week recheck reveals, and which markers matter most for long-term safety when running tesamorelin beyond six months.

Why Baseline IGF-1 Levels Predict Tesamorelin Response

IGF-1 (insulin-like growth factor 1) is the primary biomarker used to confirm that tesamorelin is stimulating endogenous growth hormone secretion. Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue. It doesn't deliver exogenous growth hormone but rather signals the pituitary gland to increase its own production. IGF-1 is synthesised in the liver in response to circulating growth hormone, making it a stable, measurable proxy for growth hormone activity over time.

Baseline IGF-1 establishes your pre-treatment level. Most adults over 40 years old present with IGF-1 levels in the lower half of the reference range (typically 90–180 ng/mL depending on age and sex). When tesamorelin works as intended, IGF-1 levels rise 30–80% above baseline within 4–8 weeks. A patient with baseline IGF-1 of 120 ng/mL should see levels rise to 160–220 ng/mL if the peptide is effectively stimulating growth hormone release. If IGF-1 remains flat or rises less than 20%, the protocol requires adjustment. Either dose escalation, injection timing changes, or investigation of pituitary dysfunction.

Without baseline data, you can't calculate the delta. Running an IGF-1 test at week eight and seeing a result of 180 ng/mL tells you nothing about efficacy unless you know where you started. Our team has found that patients who skip baseline testing frequently misinterpret normal-range IGF-1 results as 'working' when their levels haven't budged from pre-treatment baselines.

Glucose and Insulin Markers: The Safety Monitor Most Protocols Underestimate

Tesamorelin's growth hormone-stimulating effect has a well-documented secondary impact on glucose metabolism. Growth hormone induces mild insulin resistance by interfering with insulin receptor signalling in muscle and adipose tissue. For most patients, this is transient and clinically insignificant. But for individuals with pre-existing insulin resistance, metabolic syndrome, or prediabetes, tesamorelin can push fasting glucose and HbA1c into diabetic range within 8–12 weeks if not monitored.

Baseline fasting glucose and HbA1c establish metabolic stability before therapy. Fasting glucose should be measured after an 8–12 hour overnight fast. Normal fasting glucose is below 100 mg/dL; prediabetic range is 100–125 mg/dL; diabetic range is ≥126 mg/dL on two separate tests. HbA1c measures average blood glucose over the preceding 90 days and is reported as a percentage. Normal is below 5.7%, prediabetic is 5.7–6.4%, diabetic is ≥6.5%.

The critical recheck occurs at 8 weeks. If fasting glucose rises more than 10 mg/dL or HbA1c increases by 0.3% or more, insulin resistance is developing and dietary intervention or dose reduction is required. Research published in The Journal of Clinical Endocrinology & Metabolism found that approximately 15–20% of tesamorelin users experience clinically significant glucose elevations requiring protocol modification. Quarterly HbA1c monitoring during long-term use catches slow metabolic drift before it becomes irreversible.

Lipid Panel Changes: Why Tesamorelin's Primary Benefit Shows Up in the Labs

Tesamorelin was FDA-approved specifically for reducing excess abdominal fat in HIV-associated lipodystrophy, and its lipid-modulating effects are among its most clinically significant outcomes. Growth hormone stimulates lipolysis. The breakdown of stored triglycerides in adipose tissue. Which leads to measurable reductions in visceral adipose tissue (VAT) and corresponding improvements in lipid profiles over 12–26 weeks.

Baseline lipid panel must include total cholesterol, LDL cholesterol (low-density lipoprotein), HDL cholesterol (high-density lipoprotein), and triglycerides. Patients with baseline triglycerides above 150 mg/dL or LDL above 130 mg/dL often see the most dramatic improvements. Clinical trials documented mean triglyceride reductions of 15–25% and LDL reductions of 8–12% after six months of tesamorelin therapy in responders.

Rechecking lipids at 12 weeks captures the early metabolic shift. If triglycerides haven't dropped or LDL hasn't improved by this point, body composition changes may still be occurring but lipid-specific benefits are unlikely to materialise. We mean this sincerely: lipid response is one of the clearest markers that tesamorelin is delivering its intended metabolic effect. Independent of subjective measures like energy or appearance.

Comparison Table: Tesamorelin Blood Work Labs Check Before After

Lab Marker	Baseline (Before Starting)	8-Week Recheck	Quarterly Monitoring	Expected Change in Responders	Professional Assessment
IGF-1	Required. Establishes pre-treatment level (typical adult range 90–220 ng/mL depending on age)	Required. Confirms growth hormone stimulation occurred	Optional unless dose adjustment planned	30–80% increase above baseline within 8 weeks	IGF-1 delta is the single most reliable biomarker of tesamorelin efficacy. Flat IGF-1 at week 8 indicates non-response
Fasting Glucose	Required. Normal <100 mg/dL, prediabetic 100–125 mg/dL, diabetic ≥126 mg/dL	Required. Detects insulin resistance development early	Required. Catches slow metabolic drift	May rise 5–15 mg/dL transiently; sustained elevation >10 mg/dL requires intervention	Patients with baseline glucose >95 mg/dL have higher risk of crossing into prediabetic range and need closer monitoring
HbA1c	Required. Normal <5.7%, prediabetic 5.7–6.4%, diabetic ≥6.5%	Required. Tracks 90-day glucose average	Required every 12 weeks during therapy	May rise 0.1–0.3%; increase >0.3% indicates developing insulin resistance	HbA1c is more stable than fasting glucose and less subject to daily variation. It's the better long-term safety marker
Lipid Panel (Total Cholesterol, LDL, HDL, Triglycerides)	Required. Establishes cardiovascular risk profile before therapy	Recommended at 12 weeks to capture early lipid-modulating effect	Recommended every 12–16 weeks	Triglycerides typically drop 15–25%, LDL drops 8–12%, HDL may rise slightly	Lipid improvement is tesamorelin's primary FDA-approved outcome. Lack of improvement by 12 weeks suggests non-response
Liver Enzymes (ALT, AST)	Recommended. Normal ALT <40 U/L, AST <35 U/L	Optional unless baseline was elevated	Optional unless baseline concerns exist	Should remain stable; elevation suggests hepatotoxicity or unrelated liver stress	Growth hormone can transiently elevate liver enzymes in 5–10% of users. Recheck if baseline was borderline high

What If: Tesamorelin Blood Work Scenarios

What If My IGF-1 Doesn't Rise After 8 Weeks on Tesamorelin?

Reduce injection timing variability and recheck at 10–12 weeks. IGF-1 response to tesamorelin depends on consistent pituitary signalling. Injecting at different times daily or skipping doses disrupts the growth hormone pulse pattern and blunts IGF-1 production. If IGF-1 remains flat after protocol tightening, pituitary dysfunction is the most likely explanation and requires endocrinologist evaluation.

What If My Fasting Glucose Rises Above 110 mg/dL During Tesamorelin Therapy?

Implement carbohydrate restriction immediately and recheck glucose in 2 weeks. Growth hormone-induced insulin resistance responds well to dietary intervention. Reducing carbohydrate intake to below 100g daily typically reverses glucose elevations within 10–14 days. If glucose remains elevated despite dietary changes, tesamorelin dose reduction from 2mg to 1mg daily often restores glucose control without sacrificing all metabolic benefit.

What If My Triglycerides Haven't Dropped After 12 Weeks?

Confirm adherence first, then evaluate dietary fat intake and alcohol consumption. Tesamorelin stimulates lipolysis, but if dietary fat intake remains high or alcohol consumption exceeds 3–4 drinks weekly, new triglyceride formation may offset the breakdown. Patients who reduce dietary fat below 20% of total calories and eliminate alcohol typically see delayed triglyceride response by week 16–20.

The Clinical Truth About Tesamorelin Lab Monitoring

Here's the honest answer: most tesamorelin protocols fail at the monitoring stage, not the dosing stage. Patients inject correctly, maintain consistency, and follow storage protocols. But skip the 8-week IGF-1 recheck because they 'feel fine' or assume the peptide is working based on subjective measures. IGF-1 doesn't lie. If it's not elevated by week eight, growth hormone secretion isn't happening and the protocol is ineffective regardless of how you feel.

The second monitoring failure is glucose complacency. Baseline fasting glucose of 98 mg/dL feels safe. It's technically normal. But it's two points away from prediabetic range. Add tesamorelin's insulin resistance effect and that patient crosses 100 mg/dL by week six without realising it. By week twelve, HbA1c has crept to 5.9% and reversal requires months of dietary restriction. Catching glucose at 103 mg/dL at the 8-week recheck allows immediate course correction before HbA1c shifts.

The evidence is clear: tesamorelin's metabolic effects. Both beneficial and adverse. Are measurable, predictable, and completely invisible without lab work. Running the peptide without baseline IGF-1, glucose, and lipids is guessing. Monitoring correctly turns tesamorelin into a precision tool with quantifiable outcomes.

If baseline labs concern you or the cost feels prohibitive, raise it before starting. Many research protocols include lab monitoring as part of the study design, and skipping it compromises both safety and data quality. When working with research-grade compounds like those available through Real Peptides, the purity and consistency of the peptide is controlled. But metabolic response variability is individual, and only lab work reveals whether your physiology is cooperating with the protocol.

Questions

Baseline labs before starting tesamorelin must include IGF-1, fasting glucose, HbA1c, a complete lipid panel (total cholesterol, LDL, HDL, triglycerides), and liver enzymes (ALT, AST). IGF-1 establishes your pre-treatment growth hormone activity level, glucose and HbA1c screen for insulin resistance risk, lipids provide a baseline for tracking tesamorelin’s primary metabolic benefit, and liver enzymes rule out hepatic contraindications. Skipping any of these markers leaves blind spots in safety and efficacy monitoring.

IGF-1 should be checked at baseline before starting tesamorelin, rechecked at 8 weeks to confirm growth hormone stimulation occurred, and then monitored every 12–16 weeks during long-term therapy if dose adjustments are being considered. The 8-week recheck is the most critical — it’s the earliest reliable point to confirm whether tesamorelin is delivering the intended pituitary response. IGF-1 levels should rise 30–80% above baseline in responders; flat or minimal increases indicate non-response and require protocol revision.

Tesamorelin does not directly cause diabetes, but it can worsen insulin resistance in patients with pre-existing metabolic dysfunction because growth hormone interferes with insulin receptor signalling. Clinical data show that 15–20% of tesamorelin users experience fasting glucose elevations requiring dietary intervention or dose reduction. Patients with baseline fasting glucose above 95 mg/dL or HbA1c above 5.5% have the highest risk and should recheck glucose at 4 weeks instead of 8 weeks to catch early changes.

If fasting glucose rises more than 10 mg/dL during tesamorelin therapy, immediate carbohydrate restriction (below 100g daily) typically reverses the elevation within 2 weeks. If glucose remains elevated despite dietary changes, reducing tesamorelin dose from 2mg to 1mg daily often restores glucose control while preserving partial metabolic benefit. Discontinuing tesamorelin entirely causes glucose to return to baseline within 4–6 weeks as growth hormone levels normalise and insulin sensitivity recovers.

Tesamorelin-induced lipid improvements become measurable at 12 weeks in most responders, with triglyceride reductions of 15–25% and LDL reductions of 8–12% documented in clinical trials. Maximal lipid-modulating effects occur at 24–26 weeks of continuous therapy. Patients who don’t show any triglyceride or LDL improvement by 16 weeks are unlikely to achieve lipid benefits even with extended use, and the protocol should be re-evaluated for adherence, dietary confounders, or non-response.

Flat IGF-1 levels after 8 weeks on tesamorelin indicate non-response — the peptide is not effectively stimulating growth hormone secretion from the pituitary gland. Common causes include inconsistent injection timing, improper peptide storage leading to degradation, or underlying pituitary dysfunction. Before assuming pituitary failure, verify injection technique, confirm daily dosing at the same time, and ensure the peptide was stored at 2–8°C after reconstitution. If IGF-1 remains unchanged after protocol correction, endocrinologist consultation is warranted.

Baseline liver enzyme testing (ALT, AST) is recommended before starting tesamorelin, especially for patients with known liver disease, alcohol use, or metabolic syndrome. Growth hormone can transiently elevate liver enzymes in 5–10% of users, typically resolving without intervention. Routine monitoring during therapy is not required unless baseline enzymes were borderline high (ALT >35 U/L, AST >30 U/L), in which case rechecking at 8 weeks and quarterly thereafter is prudent.

You can’t reliably assess tesamorelin efficacy without lab work — subjective measures like energy, sleep quality, or appearance are too variable and influenced by placebo effect. IGF-1 is the definitive biomarker proving growth hormone stimulation occurred, and lipid panels quantify the metabolic benefit tesamorelin was designed to deliver. Skipping labs means relying on guesswork instead of data, which is particularly problematic because non-responders (10–15% of users) feel subjectively ‘fine’ while receiving zero physiological benefit from the peptide.

An HbA1c increase of 0.1–0.2% during tesamorelin therapy is common and does not require stopping the peptide if baseline HbA1c was normal. If HbA1c rises by 0.3% or more, or if it crosses into prediabetic range (≥5.7%), dietary intervention and dose reduction should be attempted first. Discontinuing tesamorelin is reserved for cases where HbA1c exceeds 6.0% despite intervention or where fasting glucose consistently exceeds 115 mg/dL — at that point, the metabolic risk outweighs the benefit.

IGF-1 is a stable biomarker synthesised in the liver in response to circulating growth hormone, making it easier to measure and more reliable than growth hormone itself. Growth hormone is secreted in pulses throughout the day, with levels fluctuating dramatically based on sleep, exercise, and food intake — a single blood draw captures only one moment in a variable cycle. IGF-1 reflects average growth hormone activity over several days, which is why it’s the standard clinical marker for assessing growth hormone status and tesamorelin response.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA